Overview

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Status:
Completed

Trial end date:
2017-08-02

Target enrollment:

Participant gender:

Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Phase:

Phase 3

Details

Lead Sponsor:

Fougera Pharmaceuticals Inc.

Treatments:

Nicotinic Acids
Tazarotene